Self-injection has quietly become one of the most significant shifts in modern healthcare delivery. From chronic disease management to fertility treatments and hormone therapies, millions of patients ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly ...
On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved an oral pill form of Wegovy — a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight loss. Until now, ...
Share on Pinterest The FDA has approved the first GLP-1 pill for weight loss. Bloomberg Creative/Getty Images In December 2025, the U.S. FDA approved an oral pill form of Wegovy for weight loss. Until ...
The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.
Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.
WILMINGTON, N.C. (WECT) - A new weight loss option is now available for people seeking alternatives to weekly injections. The Wegovy pill became available on Monday, offering the first oral option for ...
Menopause clinics across the U.S. are hearing from women who are having trouble filling prescriptions for estrogen patches, a common hormone replacement therapy.
The MarketWatch News Department was not involved in the creation of this content. CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ("Enable") a healthcare innovation company ...
A previous version of this story had an incorrect title for Brian Dunkin. He is the chief medical officer of endoscopy at Boston Scientific. The story has been corrected. Millions of Americans have ...
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results